Editing Mesothelioma Treatment Centers (section)

=== Pivotal Ongoing Trials ===

'''DREAM3R Trial (NCT04334759)''': This Phase III study comparing durvalumab with chemotherapy against physician's choice treatment has enrolled 534 patients across 57 global sites. Results may establish a new first-line standard of care. Patients interested in enrollment can inquire through their mesothelioma treatment center or discuss eligibility requirements with their oncologist.

'''eVOLVE-Meso Trial (NCT06097728)''': Launched in November 2023, this study tests volrustomig, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy in '''825 patients'''—representing one of the largest mesothelioma trials ever conducted. Primary completion is expected in March 2027, with results potentially reshaping treatment paradigms.

'''CAR-T Cell Programs''': Memorial Sloan Kettering's mesothelin-targeted CAR-T programs achieve '''23.9 months median overall survival''' when combined with pembrolizumab. The STAR-101 study testing SynKIR-110 CAR-T cells received FDA Fast Track designation in 2023, while the National Cancer Institute's TNhYP218 trial recently launched recruitment for 100 patients with advanced CAR design promising improved durability.